Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Vertex Pharmaceuticals Inc VX-548 Phase 3 Results in Acute Pain Conference Call Transcript

Jan 30, 2024 / 01:00PM GMT
Release Date Price: €410.35 (+2.90%)
Operator

Good day, and welcome to the Vertex Pharmaceuticals VX-548 Phase III pivotal program results and Acute Pain Conference Call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma'am.

Susie Lisa
Vertex Pharmaceuticals Incorporated - SVP of IR

Thank you, Chuck. Good morning all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations. It is my pleasure to welcome you to this conference call to discuss results from Vertex's Phase III pivotal development program of VX-548 in acute pain.

Making prepared remarks on today's call, we have Dr. Reshma Kewalramani, Vertex's CEO and President; joining her for the question-and-answer portion of the call are Stuart Arbuckle, Chief Operating Officer; and Charlie Wagner, Chief Financial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website.

We will make forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot